The cardioprotective effects of novel Na+/H+ exchanger inhibitor TY-51924 on ischemia/reperfusion injury

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 4, 2014, Pages 351-359

  Sasamori, Jun ^a   Hasegawa, Takeshi ^a   Takaya, Akiyuki ^a   Watanabe, Yoshiaki ^a   Tanaka, Marie ^a   Ogino, Yamato ^a   Chiba, Toshiki ^a   Aihara, Kazuyuki ^a  

^a TOA EIYO LTD   (Japan)

Author keywords

cardioprotection; myocardial ischemia reperfusion injury; NHE inhibitor; TY 51924

Indexed keywords

CARIPORIDE; COMPLEMENTARY DNA; S 3226; SODIUM 3 GUANIDINOCARBONYL 2 METHYL 6,7,8,9 TETRAHYDRO 5H CYCLOHEPTA[B]PYRIDINE 9 YLMETHYL SULFATE MONOETHANOLATE; SODIUM CHANNEL BLOCKING AGENT; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; SODIUM PROTON EXCHANGE PROTEIN 2; SODIUM PROTON EXCHANGE PROTEIN 3; TY 51924; UNCLASSIFIED DRUG; 3-GUANIDINOCARBONYL-2-METHYL-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA(B)PYRIDINE-9-YLMETHYL SULFURIC ACID; CARDIOTONIC AGENT; CREATINE KINASE; GUANIDINE DERIVATIVE; SULFATE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DOG; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; LOW DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DRUG EFFECTS; HEMODYNAMICS; ISOMERISM; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; CREATINE KINASE; DOGS; GUANIDINES; HEMODYNAMICS; ISOMERISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; REPERFUSION INJURY; SODIUM-HYDROGEN ANTIPORTER; SULFURIC ACID ESTERS;

EID: 84898597561     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000055     Document Type: Article

References (33)

1. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008; 118:2057-2062.
2. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76:1713-1719.
3. Wang QD, Pernow J, Sjoquist PO, et al. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res. 2002; 55:25-37.
4. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol. 2008;103:501-513.
5. + exchange and its inhibition in cardiac ischemia and reperfusion. Basic Res Cardiol. 1993;88:443-455.
6. Williams IA, Xiao XH, Ju YK, et al. The rise of [Na(+)] (i) during ischemia and reperfusion in the rat heart-underlying mechanisms. Pflugers Arch. 2007;454:903-912.
7. 2+ exchanger at the time of myocardial reperfusion on hypercon-tracture and cell death. Cardiovasc Res. 2002;55:739-748.
8. Garcia-Dorado D, Ruiz-Meana M, Inserte J, et al. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res. 2012;94:168-180.
9. + exchange inhibitor, on ischemia/reperfusion injury. Eur J Pharmacol. 2000;404:221-229.
10. Gumina RJ, Mizumura T, Beier N, et al. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther. 1998;286:175-183.
11. +-exchange inhibitor, FR183998, shows car-dioprotective effects in rats with cardiac ischemia and reperfusion. J Cardiovasc Pharmacol. 1999;34:848-856.
12. + exchanger-1 inhibitor, on ischemia and reperfusion-induced myocardial infarction in rats and dogs. Fundam Clin Pharmacol. 2007;21:255-263.
13. + exchange inhibitor, in rabbits. Eur J Pharmacol. 2005;521:115-123.
14. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation. 2000;102:3032-3038.
15. Mentzer RM Jr, Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg. 2008;85:1261-1270.
16. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardi-oprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001;38:1644-1650.
17. + exchanger during ischemia and reperfusion. Cardiovasc Res. 2003;57:934-941.
18. Touret N, Tanneur V, Godart H, et al. Characterization of sabiporide, a new specific NHE-1 inhibitor exhibiting slow dissociation kinetics and cardioprotective effects. Eur J Pharmacol. 2003;459:151-158.
19. + antiport activity in hamster fibroblasts precludes growth at neutral and acidic pH. Proc Natl Acad Sci USA. 1984;81: 4833-4837.
20. Scholz W, Albus U, Counillon L, et al. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res. 1995;29:260-268.
21. Hropot M, Juretschke HP, Langer KH, et al. S3226, a novel NHE3 inhibitor, attenuates ischemia-induced acute renal failure in rats. Kidney Int. 2001;60:2283-2289.
22. Sasamori J, Aihara K, Yoneyama F, et al. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146). J Cardiovasc Pharmacol. 2006;47:614-620.
23. Van Wylen DG, Willis J, Sodhi J, et al. Cardiac microdialysis to estimate interstitial adenosine and coronary blood flow. Am J Physiol. 1990;258 (pt 2):H1642-H1649.
24. Piwnica-Worms D, Jacob R, Horres CR, et al. Na/H exchange in cultured chick heart cells. pHi regulation. J Gen Physiol. 1985;85:43-64.
25. Lorrain J, Briand V, Favennec E, et al. Pharmacological profile of SL 59. 1227, a novel inhibitor of the sodium/hydrogen exchanger. Br J Pharmacol. 2000;131:1188-1194.
26. Sasamori J, Aihara K, Uchibori T, et al. Cardioprotective effects of 2-octynyladenosine (YT-146) in ischemic/reperfused rat hearts. J Cardi-ovasc Pharmacol. 2011;57:166-173.
27. Raveaud S, Verdetti J, Faury G. Nicorandil protects ATP-sensitive potassium channels against oxidation-induced dysfunction in cardiomyocytes of aging rats. Biogerontology. 2009;10:537-547.
28. Cox GA, Lutz CM, Yang CL, et al. Sodium/hydrogen exchanger gene defect in slow-wave epilepsy mutant mice. Cell. 1997;91:139-148.
29. Hubler N, Gottschling B, Jacobs M, et al. Functional observational battery and motor activity in rats after single administration of two NHE 1 inhibitors. Toxicol Appl Pharmacol. 2005;208:266-276.
30. + exchange inhibitor, T-162559. Br J Pharmacol. 2002;135:1995-2003.
31. Karmazyn M. NHE-1: still a viable therapeutic target. J Mol Cell Car-diol. 2013;61:77-82.
32. Gross GJ, Buck JD, Warltier DC, et al. Separation of overlap and collateral perfusion of ischemic canine myocardium: important considerations in the analysis of vasodilator-induced coronary steal. J Cardiovasc Pharmacol. 1982;4:254-263.
33. 2+ exchange. Circ Res. 1989;65:1045-1056.